Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opko

- PMLiVE

Pfizer CEO says oral COVID-19 pill could be ready by the end of the year

Company initiated a phase 1 study of the drug last month

Empowering patients empowers results

Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in adolescents

Vaccine was found to be safe and effective in adolescents aged 12 to 15 years old

- PMLiVE

BioNTech forecasts €9.8bn in sales of Pfizer-partnered COVID-19 vaccine in 2021

Company also raised full year manufacturing capacity target for vaccine to 2.5 billion doses

- PMLiVE

Single Pfizer/BioNTech dose induces strong immune response to COVID-19

Study finds 99% of people generated a robust immune response against COVID-19 after single vaccine dose

- PMLiVE

Pfizer launches early study of COVID-19 antiviral therapeutic

Therapeutic candidate has demonstrated 'potent' in vivo activity against SARS-CoV-2

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

There’s No Going Back: How COVID-19 will Change Pharma Forever

Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches...

Impetus Digital

- PMLiVE

EU announces ‘top-up’ of ten million Pfizer/BioNTech vaccines in Q2

Brings total number of doses of the vaccine to be delivered in Q2 to over 200 million

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

Neutralisation of variant 'roughly equivalent' to original SARS-CoV-2 strain

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links